The FDA is reviewing Epkinly to treat relapsed or refractory follicular lymphoma. The target date is in August 2023.
The FDA has granted priority review review to the supplemental biologics license application (sBLA) for Epkinly (epcoritamab-bysp), a subcutaneously administered T-cell engaging bispecific antibody to treat adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of therapy. A priority review shortens the agency’s review time to six months; the target date is in August 2024.
Follicular lymphoma is a slow-growing form of non-Hodgkin’s lymphoma that arises from B-lymphocytes. It accounts for 20% to 30% of all non-Hodgkin’s lymphoma cases.
Developed by AbbVie and Genmab, Epkinly was approved in May 2023 as a third-line therapy to treat patients with diffuse large B-cell lymphoma (DLBCL) treatment. Epkinly that targets CD3 on the surface of T cells and CD20 on the surface of B cells. Epkinly is a monthly therapy with a cost of $37,500 per month. Copay assistance is available through Genmab’s MyNavCare program. The current maximum benefit is $25,000 per year. In 2023, Epkinly generated $31 million in worldwide revenue for AbbVie. Under the agreement with AbbVie, Genmab receives royalties of between 22% and 26% on net sales outside the United States and Japan. Genmab and AbbVie evenly split product sales in other territories. Genmab’s financial statements for 2023 did not break out sales figures for Epkinly.
The sBLA is based on results from the phase 1/2 EPCORE NHL-1 clinical trial, which demonstrated high overall and complete responses in patients with relapsed or refractory follicular lymphoma after two or more lines of therapy. Patients treated with Epkinly experienced 82% overall response rate including 63% complete response rate at a median follow up of 17.4 months. An estimated 85% and 74% of patients who experienced a complete response remained responsive to treatment at 12 and 18 months, respectively.
The most common treatment-emergent adverse event was cytokine release syndrome with 67% occurrence. Additional treatment-emergent adverse events include injection-site reaction, COVID-19, fatigue, neutropenia, diarrhea and pyrexia. Treatment-emergent adverse event leading to treatment discontinuation occurred in 19% of patients, and death related to treatment occurred in 13 patients.
Data from the follicular lymphoma cohorts of the trial were presented at the Annual Meeting and Exposition of the American Society of Hematology (ASH) in December 2023.
“Despite treatment advances for patients with follicular lymphoma whose disease has unfortunately progressed, treating relapsed or refractory follicular lymphoma remains highly challenging, particularly as a third-line treatment,” Catherine Thieblemont, M.D., Ph.D., head of the hemato-oncology department, Paris University, Hôpital Saint-Louis Assistance-Publique-Hopitaux de Paris (APHP) in Paris, said in a press release. “The patients in this trial represent a historically difficult-to-treat patient population. The data presented today are especially notable because they demonstrated high overall and complete response rates for this investigational therapy and a preview for its potential as a treatment option.”
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More